gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 29 May 2015.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, V1a, STAT3
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Supplier
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
Pilot Study Evaluating Regulatory T Cell-Promoting Immunosuppression and Nonimmunogenic Donor Antigen Delivery in a Nonhuman Primate Islet Allotransplantation Model.
New
Markmann et al., Boston, United States. In Am J Transplant, 26 Jun 2015
Here, we report an immunotherapy regimen that combines 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (ECDI)-treated donor lymphoid cell infusion (ECDI-DLI) with thymoglobulin, anti-interleukin-6 receptor antibody and rapamycin to achieve prolonged allogeneic islet graft survival in a nonhuman primate (NHP) model.
A Phase I/II Trial of the Interleukin-6 Receptor Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
New
Jordan et al., Los Angeles, United States. In Transplantation, 25 Jun 2015
Here, we undertook a phase I/II pilot study of DES using a novel drug (anti-IL-6 receptor (IL-6R),Tocilizumab [TCZ]) + intravenous Ig (IVIg) to assess safety and limited efficacy.
Interleukin-6 and interleukin-6 receptor expression, localization, and involvement in pain-sensing neuron activation in a mouse intervertebral disc injury model.
New
Ohtori et al., Chiba, Japan. In J Orthop Res, 23 Jun 2015
The objective of this study is to elucidate the mechanism of local IL-6 and IL-6 receptor (IL-6R) expression after IVD injury as well as determine the involvement of IL-6/IL-6 signaling in discogenic pain.
Epigenetic Alterations of IL-6/STAT3 Signaling by Placental Stem Cells Promote Hepatic Regeneration in a Rat Model with CCl4-induced Liver Injury.
New
Kim et al., South Korea. In Int J Stem Cells, 31 May 2015
The concentration of hIL-6 in supernatants and the proliferation of CCl4-treated rat hepatic cells were enhanced by co-culturing with CP-MSCs (p<0.05), while the methylation of IL-6/IL-6R and STAT3 by CP-MSC transplantation decreased.
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
Review
New
Rose-John et al., Kiel, Germany. In Curr Opin Immunol, 04 Apr 2015
However, a plethora of studies in the last decade has convincingly shown that only signaling via the soluble IL-6R (trans-signaling) accounts for the deleterious effects of IL-6, whereas classic signaling via the membrane-bound receptor is essential for the regenerative and anti-bacterial effects of IL-6 (classic signaling).
Biomarker identification and effect estimation on schizophrenia - a high dimensional data analysis.
New
Niebuhr et al., Silver Spring, United States. In Front Public Health, Dec 2014
In DGR analysis of serum specimens of US military service members with a diagnosis of schizophrenia from 1992 to 2005 and their controls, Alpha-1-Antitrypsin (AAT), Interleukin-6 receptor (IL-6r) and connective tissue growth factor were selected to identify schizophrenia for males; and AAT, Apolipoprotein B and Sortilin were selected for females.
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
New
Impact
Hill et al., Brisbane, Australia. In Lancet Oncol, Dec 2014
Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways.
Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
New
Impact
Mauri et al., Udine, Italy. In Nat Med, Nov 2014
Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals.
Interleukin-6 and its receptors: a highly regulated and dynamic system.
Review
New
Garbers et al., Kiel, Germany. In Cytokine, Nov 2014
IL-6 induces intracellular signaling pathways after binding to its membrane-bound receptor (IL-6R), which is only expressed on hepatocytes and certain subpopulations of leukocytes (classic signaling).
Chimeric antigen receptor T cells for sustained remissions in leukemia.
New
Impact
Grupp et al., Australia. In N Engl J Med, Nov 2014
Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.
Immunotherapy for Graves' ophthalmopathy.
Review
New
Salvi, Milano, Italy. In Curr Opin Endocrinol Diabetes Obes, Oct 2014
A recent open study with tocilizumab, an anti-soluble interleukin-6 receptor, has shown inactivation of Graves' ophthalmopathy.
Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Review
New
Grupp et al., Philadelphia, United States. In Cancer J, Mar 2014
One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab.
Interleukin-6: possible biological roles during exercise.
Review
Dela et al., Rīga, Latvia. In Ejss (champaign), 2013
Interleukin-6 (IL-6) is a multifunctional cytokine that exerts its modulatory effects on cells that express membrane bound IL-6 receptors; however, IL-6 in a complex with soluble IL-6R can bind to any cell that express glycoprotein 130 (gp130).
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Review
Impact
Weiss et al., Toronto, Canada. In Nat Rev Immunol, 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
Impact
PRCSG et al., Roma, Italy. In N Engl J Med, 2013
METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
GeneRIF
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
GeneRIF
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
GeneRIF
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Impact
GeneRIF
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
GeneRIF
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
share on facebooktweetadd +1mail to friends